BYSI Summary

  1. NASDAQ
  2. >
  3. BYSI
TickerBYSI
DescriptionBEYONDSPRING INC
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Employees91
Next Earnings DateNovember 30th, 2021
IV147.139576%
IV Percentile83rd
IV Rank26.48%
IV Skew27.791431
IV Skew Percentile97th
IV Skew SentimentBearish
Option Volume5,292
Volume3,099,188
Price$4.08
Previous Close$4.44
52-Week High$33.00
52-Week Low$3.64
50-Day Moving Avg.$14.10
200-Day Moving Avg.$15.28
10-Day Avg. Volume8,191,269
20-Day Avg. Volume2,879,947
30-Day Avg. Volume2,906,852
3-Month Avg. Volume1,593,337
EPS-$1.92
Outstanding Shares39,106,476
Market Capitalization$192,838,000
CurrencyUSD
UpdatedDecember 3rd, 2021